With a focus is on pulmonary disease and kinase inhibitor technology, Pulmokine's objective is to develop new therapies for hard-to-treat lung conditions like pulmonary arterial hypertension (PAH) and related disorders. These include pulmonary arterial fibrosis/interstitial lung disease, sarcoidosis and lung cancer. The firm has an exclusive license from YM Biosciences to develop a portfolio of JAK1/JAK2 and PDGFR inhibitors for PAH. In 2015, a partnership was announced involving a $1m commitment meant to accelerate the development of the lead drug candidate being developed by Pulmokine, PK10571, for the treatment of pulmonary arterial hypertension (PAH) and enable the initiation of its phase 1 clinical trial. Atthetime, preclinical results of the firm's inhaled PDGF receptor inhibitor were quite compelling, showing a meaningful decrease in pulmonary pressures in animal models of PAH.â By interfering with the PDGF receptor pathway, it seemedlikely that the firm's lead candidate had the potential to address an underlying cause of PAH, not merely to alleviate its symptoms
